SCHEMBL2001891

SCHEMBL2001891

O=C(O)c1nc2ccccc2cc1-c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.57
KDM4E B2RXH2 4/20 0.57
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
MAPT P10636 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
MGAM O43451 2/20 0.46
PDE10A Q9Y233 3/20 0.44
LMNA P02545 2/20 0.44
GLA P06280 1/20 0.43
HPGD P15428 1/20 0.43
ACHE P22303 1/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
DHODH Q02127 1/20 0.41
ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridine SCHEMBL2285312 0.92 ALDH1A1 (0.50) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL1131468 0.86 IKBKB (0.50) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL3118854 0.82 KDM4E (0.47) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL8329240 0.81 ALDH1A1 (0.56) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL4602438 0.81 ALDH1A1 (0.53) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL11089095 0.79 KDM4E (0.50) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL31556386 0.79 KDM4E (0.50) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL28026248 0.79 TARBP2 (0.50) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL60874 0.78 ALDH1A1 (0.61) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL70017 0.78 ALDH1A1 (0.61) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0261426-B1 FREEZE-DRIED PHARMACEUTICAL COMPOSITIONS OF PHENYLQUINOLINE CARBOXYLIC ACIDS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1992-11-04 EP claimed
US-4889862-A BILE SALT STABILIZER FOR ANTITUMOR INJECTABLE SOLUTION E. I. DU PONT DE NEMOURS AND COMPANY (US) 1989-12-26 US claimed
EP-0261426-A1 Freeze-dried pharmaceutical compositions of phenylquinoline carboxylic acids THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1988-03-30 EP claimed
EP-0036145-B1 AN ORALLY ADMINISTERED DRUG FORM COMPRISING A POLAR BIOACTIVE AGENT AND AN ADJUVANT INTERx RESEARCH CORPORATION (US) 1985-05-29 EP claimed
US-11495755-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2022-11-08 US disclosed
EP-3719099-A1 PHOSPHORESCENT MATERIALS Universal Display Corporation (US) 2020-10-07 EP disclosed
CN-111632100-A Traditional Chinese medicine oral liquid for treating goose gout and preparation method thereof 安徽亿牧生物科技有限公司 2020-09-08 CN disclosed
US-20200176693-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2020-06-04 US disclosed
EP-3327100-B1 PHOSPHORESCENT MATERIALS UNIVERSAL DISPLAY CORP (US) 2020-05-06 EP disclosed
US-10600975-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2020-03-24 US disclosed
US-20190157576-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2019-05-23 US disclosed
US-10230060-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2019-03-12 US disclosed
EP-0261426-A1 Freeze-dried pharmaceutical compositions of phenylquinoline carboxylic acids THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1988-03-30 EP disclosed
US-4680299-A ANTITUMOR AGENTS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1987-07-14 US disclosed
US-4680299-A ANTITUMOR AGENTS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1987-07-14 US disclosed
US-4639454-A LYMPHOID LEUKEMIA E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-01-27 US disclosed
EP-0036145-B1 AN ORALLY ADMINISTERED DRUG FORM COMPRISING A POLAR BIOACTIVE AGENT AND AN ADJUVANT INTERx RESEARCH CORPORATION (US) 1985-05-29 EP disclosed
EP-0133244-A2 Phenylquinolinecarboxylic acids and derivatives as antitumor agents E.I. DU PONT DE NEMOURS AND COMPANY (US) 1985-02-20 EP disclosed
EP-0133244-A2 Phenylquinolinecarboxylic acids and derivatives as antitumor agents E.I. DU PONT DE NEMOURS AND COMPANY (US) 1985-02-20 EP disclosed
EP-0133244-A2 Phenylquinolinecarboxylic acids and derivatives as antitumor agents E.I. DU PONT DE NEMOURS AND COMPANY (US) 1985-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200176693-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES RUVBL2, TERT, OR10J3 ALDH1A1 1888/4885KDM4E 3403/4885MEN1 993/4885
US-11495755-B2 Organic electroluminescent materials and devices RUVBL2, TERT, OR10J3 ALDH1A1 1888/4885KDM4E 3403/4885MEN1 993/4885
US-10230060-B2 Organic electroluminescent materials and devices RUVBL2, OR10J3, EML4 ALDH1A1 734/4885KDM4E 3060/4885MEN1 2129/4885
US-10600975-B2 Organic electroluminescent materials and devices TERT, OR10J3, RUVBL2 ALDH1A1 1294/4885KDM4E 3344/4885MEN1 947/4885
US-20190157576-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES PIEZO1, ORAI2, PORCN ALDH1A1 3140/4885KDM4E 3726/4885MEN1 540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.